Expression of Cytokine Signaling Genes in Morbidly Obese Patients with Non-Alcoholic Steatohepatitis and Hepatic Fibrosis

被引:42
作者
Estep, J. Michael [1 ,2 ,3 ]
Baranova, Ancha [1 ,2 ,3 ]
Hossain, Noreen [3 ]
Elariny, Hazem [3 ]
Ankrah, Kathy [3 ]
Afendy, Arian [1 ,3 ]
Chandhoke, Vikas [2 ,3 ]
Younossi, Zobair M. [1 ,2 ,3 ]
机构
[1] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA 22042 USA
[2] George Mason Univ, Mol & Microbiol Dept, Ctr Study Genom Liver Dis, Fairfax, VA 22030 USA
[3] Inova Hlth Syst, Translat Res Inst, Falls Church, VA USA
关键词
NASH; Fibrosis; Morbid obesity; FATTY LIVER-DISEASE; VISCERAL ADIPOSE-TISSUE; INSULIN-RESISTANCE; METABOLIC SYNDROME; INFLAMMATION; ACTIVATION; RELEASE; CELLS;
D O I
10.1007/s11695-009-9814-x
中图分类号
R61 [外科手术学];
学科分类号
摘要
White adipose tissue (WAT) from visceral adiposity plays an important role in the pathogenesis of non-alcoholic steatohepatitis (NASH). Development of NASH and its progression to fibrosis is partially due to cytokines and adipokines produced by WAT. The aim of this study was to assess the association of hepatic fibrosis and NASH by evaluating the intrinsic differences in the inflammatory cytokine signaling in the visceral adipose tissue obtained from morbidly obese patients. We used targeted microarrays representing human genes involved in the inflammatory and fibrogenic reactions to profile visceral adipose samples of 15 well-matched NASH patients with and without fibrosis. Additionally, visceral adipose samples were subjected to real-time polymerase chain reaction profiling of 84 inflammations related genes. Eight genes (CCL2, CCL4, CCL18, CCR1, IL10RB, IL15RA, and LTB) were differentially expressed in NASH with fibrosis. Additionally, an overlapping but distinct list of the differentially expressed genes were found in NASH with type II diabetes (DM; IL8, BLR1, IL2RA, CD40LG, IL1RN, IL15RA, and CCL4) as compared to NASH without DM. Inflammatory cytokines are differentially expressed in the adipose tissue of NASH with fibrosis, as well in NASH with DM. These findings point at the interaction of adipose inflammatory cytokines, DM, hepatic fibrosis in NASH, and its progression to cirrhosis and end-stage liver disease.
引用
收藏
页码:617 / 624
页数:8
相关论文
共 50 条
[31]   Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery [J].
Harnois, F ;
Msika, S ;
Sabaté, JM ;
Mechler, C ;
Jouet, P ;
Barge, J ;
Coffin, B .
OBESITY SURGERY, 2006, 16 (02) :183-188
[32]   Prevalence and Predictive Factors of Non-Alcoholic Steatohepatitis (NASH) in Morbidly Obese Patients Undergoing Bariatric Surgery [J].
Florence Harnois ;
Simon Msika ;
Jean-Marc Sabaté ;
Charlotte Mechler ;
Pauline Jouet ;
Jeanine Barge ;
Benoit Coffin .
Obesity Surgery, 2006, 16 :183-188
[33]   Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis [J].
Tsang, SWC ;
Ng, WF ;
Wu, BPY ;
Chow, DA ;
Li, ETH ;
Wong, TC .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 (01) :116-121
[34]   Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis [J].
Satapathy, Sanjaya K. ;
Sakhuja, Puja ;
Malhotra, Veena ;
Sharma, Barjesh C. ;
Sarin, Shiv K. .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (05) :634-638
[35]   Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis [J].
Younossi, ZM ;
Gorreta, F ;
Ong, JP ;
Schlauch, K ;
Del Giacco, L ;
Elariny, H ;
Van Meter, A ;
Younoszai, A ;
Goodman, Z ;
Baranova, A ;
Christensen, A ;
Grant, G ;
Chandhoke, V .
LIVER INTERNATIONAL, 2005, 25 (04) :760-771
[36]   Long-term Results of Bariatric Surgery for Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis Treatment in Morbidly Obese Japanese Patients [J].
Uehara, Daisuke ;
Seki, Yosuke ;
Kakizaki, Satoru ;
Horiguchi, Norio ;
Tojima, Hiroki ;
Yamazaki, Yuichi ;
Sato, Ken ;
Yamada, Masanobu ;
Uraoka, Toshio ;
Kasama, Kazunori .
OBESITY SURGERY, 2019, 29 (04) :1195-1201
[37]   Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis [J].
Amano, Yuichiro ;
Tsuchiya, Shuntarou ;
Imai, Mayumi ;
Tohyama, Kimio ;
Matsukawa, Jun ;
Isono, Osamu ;
Yasuno, Hironobu ;
Enya, Kazuaki ;
Koumura, Emiko ;
Nagabukuro, Hiroshi .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 497 (01) :207-213
[38]   PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis [J].
Francque, Sven ;
Verrijken, An ;
Caron, Sandrine ;
Prawitt, Janne ;
Paumelle, Rejane ;
Derudas, Bruno ;
Lefebvre, Philippe ;
Taskinen, Marja-Riitta ;
Van Hul, Wim ;
Mertens, Ilse ;
Hubens, Guy ;
Van Marck, Eric ;
Michielsen, Peter ;
Van Gaal, Luc ;
Staels, Bart .
JOURNAL OF HEPATOLOGY, 2015, 63 (01) :164-173
[39]   Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis [J].
Li, Yadi ;
Yang, Yan ;
Li, Yufang ;
Zhang, Ping ;
Ge, Gaiying ;
Jin, Jing ;
Du, Ting ;
Ma, Maiyan ;
Na, Li ;
Ding, Lu ;
Sheng, Huiping .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (11)
[40]   Beneficial Effects of Vitamin D Treatment in an Obese Mouse Model of Non-Alcoholic Steatohepatitis [J].
Jahn, Daniel ;
Dorbath, Donata ;
Kircher, Stefan ;
Nier, Anika ;
Bergheim, Ina ;
Lenaerts, Kaatje ;
Hermanns, Heike M. ;
Geier, Andreas .
NUTRIENTS, 2019, 11 (01)